Analysts have made adjustments to their ratings on several healthcare stocks.
Berenberg has initiated coverage of AbbVie (ABBV, Financial) with a ‘Hold’ rating. The analyst established a price target of $105 per share, which represents a 10% upside.
The stock in AbbVie climbed 31% during 52 weeks of trading. It is trading below the 200, 100 and 50-SMA lines.
The 52-week range is $69.38 to $125.86 per share. The stock has a market capitalization of $144.76 billion, a price-book ratio of 42.7 times, a price-sales ratio of 4.89 times and a price-earnings of 24.04 times.
The share price is above the Peter Lynch Earnings Line (P/E = 15) of $59.5 per share and the Price at Med P/E without NRI (P/E = 19.56) of $77.6 per share.
Abbvie has a forward dividend of $3.84 per share, granting 3.96%. The average target price of $113.23 is a mean of 22 estimates ranging from $78 to $157 per share. The stock in AbbVie has a recommendation rating of 2.4 out of 5.
The forward price-earnings ratio is 10.69 times and the earnings per share for fiscals 2018 and 2019 are $7.81 and $8.94.
Shares of Bluebird bio (BLUE, Financial) commenced with a ‘Buy’ rating at Gabelli. The stock has an average target price of $219.72 per share, which is a 22% growth from the current price of $180.3 per share.
The stock is up 88% during the last 52 weeks. The current share price is below the 100-SMA line but above the 50 and 200-SMA lines.
The stock in Bluebird bio has a market capitalization of $9.04 billion. The share price falls in the 52-weeks range of $85.65 to $236.17 per share. The price-book ratio is 5.74 times and the price-sales ratio is 182.88 times.
The company is not paying dividends.
GuruFocus assigns Bluebird a financial strength rating of 6 out of 10 and a profitability and growth rating of 2 out of 10.
Morgan Stanley has granted Humana (HUM, Financial) with an ‘Overweight’ rating and a $362 price target. The price target is a 14.7% upside from the current share price of $315.7. The stock has climbed 32% for during the last 52 weeks and is trading below the 200, 100 and 50-SMA lines.
The 52-week range is $229.84 to $319.44 per share and the market capitalization is $43 billion.
Humana has a price-book ratio of 4.31 times, a price-sales ratio of 0.83 times and a price-earnings ratio of 24.66 times.
According to the Peter Lynch chart, the stock in Humana is not trading at the most compelling prices.
The company has a forward dividend of $2 per share, yielding 0.64%.
The forward price-earnings ratio of 22.73 times multiplied by a forecasted earnings per share of $15.42 yields a value of $350.50 per share. The stock has a recommendation rating of 1.9 out of 5. The average target price stands at $323 per share.
MEDNAX (MD, Financial) commenced with a rating of ‘Market Perform’ at Leerink. The analyst has also set a price target of $50 per share, which is 14.2% higher than the current share price. After a 25% decline over the trailing 12 months, the stock in Mednax is currently below the 200, 100 and 50-SMA lines.
The current share price of $43.80 belongs to a 52-week range of $40.56 to $63.04 per share and leads to a market capitalization of $4 billion. The stock has a price-book ratio of 1.35 times, a price-sales ratio of 1.19 times and a price-earnings ratio of 12.31 times.
According to the Peter Lynch chart, the stock in Mednax should currently be standing at convenient valuations.
The stock has a recommendation rating of 2.7 out of 5 and an average target price of $52.08 per share. The forward price-earnings ratio is 10.64 times versus an industry of 20.66 times. For full fiscals 2018 and 2019, analysts forecast an earnings per share of $4.14 and $4.45.
The company is not distributing dividends.
GuruFocus assigns a financial strength rating of 5 out of 10 and a growth and profitability rating of 8 out of 10.
Goldman Sachs upgraded Johnson & Johnson (JNJ, Financial) to 'Neutral' and set a $134 price target. The price target is a 4.8% upside from the current market valuation of $127.76.
For the last 52 weeks of trading, Johnson & Johnson is down 4% and trading below the 200-SMA line. The share price is above the 50 and 100-SMA lines.
The stock in Johnson & Johnson has a market capitalization of $342.67 billion. It is trading its book value per share at 5.42 times and its trailing 12-month sales per share at 4.45 times. The industry is standing with medians of 2.96 times for the price-book ratio and 3.25 times for the price-sales ratio. The stock in Johnson & Johnson has a price-earnings ratio of 327.59 times versus an industry median of 26.44 times.
The share price of Johnson & Johnson is above the Peter Lynch Earnings Line of (P/E = 15) and the Price at Med P/E without NRI (P/E = 20.97).
The market capitalization is $342.67 billion. The 52-week share price ranges between $118.62 and $148.32.
Johnson & Johnson has a forward dividend of $3.6, granting 2.86%.
The average target price is $142.48 per share and the recommendation rating is 2.4 out of 5.
If we multiply the forward price earnings ratio of 15.53 times by a forecast earnings per share of $8.40, it yields a value of $129.75 per share.
Goldman Sachs also downgraded Perrigo (PRGO, Financial) to a Sell rating with a price target of $74. The stock climbed 3% over the last 52 weeks of trading to a share price of $76. The share price is below the 200 and 100-SMA lines but above the 50-SMA line.
The market capitalization of Perrigo is $10.53 billion, and the 52-week range is $63.68 to $95.93 per share.
The price-book ratio is 1.73 times, the price-sales ratio is 2.17 times and the price-earnings ratio is 84.47 times.
The Peter Lynch chart indicates that Perrigo is not trading cheaply.
The stock has a forward dividend yield of 76 cents, yielding 1%. The forward price-earnings ratio is 14.66 times versus an industry median of 20 times. For fiscals 2019 and 2018, consensus is for net earnings of $5.24 per share and $5.63 per share.
The recommendation rating is 2.6 out of 5 and the average target price is $89 per share.
GuruFocus assigns a financial strength rating of 5 out of 10 and a profitability and growth rating of 7 out of 10.
(Disclosure: I have no positions in any securities mentioned in this article.)
